Summary: This publication reports only the design and baseline characteristics of the two-part, phase 3, randomised, double-blind, placebo-controlled ESSENCE trial (NCT04822181) of weekly subcutaneous semaglutide 2.4 mg in 800 participants with biopsy-proven MASH and fibrosis stage 2 or 3. Among the first 800 randomised, 31.3% had fibrosis stage 2 and 68.8% had stage 3, mean age was 56 years, 57.1% were female, mean BMI was 34.6 kg/m2, 55.5% had type 2 diabetes, and more than 99% met at least one MASLD cardiometabolic criterion. No efficacy outcomes are presented in this paper.
PICO Summary
| Element | Detail |
|---|---|
| Population | First 800 randomised participants with biopsy-proven MASH and fibrosis stage 2 (250; 31.3%) or stage 3 (550; 68.8%); two-part, phase 3, randomised, double-blind, placebo-controlled multicentre trial (NCT04822181). Mean age 56 (SD 11.6) years; 57.1% female; mean BMI 34.6 (SD 7.2) kg/m2; 55.5% with type 2 diabetes; >99% with at least one MASLD cardiometabolic criterion. |
| Intervention | Subcutaneous semaglutide 2.4 mg once weekly. Arm-level allocation numbers were not reported in this baseline/design paper. |
| Comparison | Matched subcutaneous placebo once weekly. Arm-level allocation numbers were not reported in this baseline/design paper. |
| Outcome | No efficacy results are reported. The two co-primary Part 1 endpoints (planned) are resolution of steatohepatitis with no worsening of fibrosis, and improvement in fibrosis with no worsening of steatohepatitis; Part 2 is based on clinical outcomes. This paper provides only baseline descriptive data, so no effect estimates, confidence intervals, p values, ARR, or NNT are available. |
Expert Commentary
This is a design and baseline-characteristics report, not an efficacy study, and it must be read as such. No treatment effect is reported, no histological or clinical outcome is measured here, and therefore no conclusion about whether semaglutide helps MASH can be drawn from this publication alone. What is offered is a well-characterised cohort: 800 participants with biopsy-proven, clinically significant fibrosis, a population enriched for stage 3 disease and metabolic comorbidity, which lends external relevance to the eventual results. The methodology is appropriately rigorous on paper, with randomisation, double blinding, placebo control, and two predefined co-primary histological endpoints, the design features that give a future readout credibility. Two cautions are warranted. First, the trial is sponsored by the manufacturer of semaglutide, and several authors are employees of that company, so independent scrutiny of the eventual efficacy and safety data will matter. Second, baseline papers can build anticipation that outpaces evidence; readers should resist inferring benefit from an encouraging design. Can I use this with my patients? Not yet. Nothing here changes prescribing, and semaglutide should not be offered for MASH on the basis of a design paper. The sensible position is to await the peer-reviewed Part 1 histological results and the longer-term Part 2 clinical outcomes before drawing any therapeutic conclusion.
References
Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, Østergaard L, Vanni D, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60(11-12):1525-1533. doi:10.1111/apt.18331